Literature DB >> 30408268

Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis.

Xiaoxiao Ma1,2, Liwen Zhang2,3, Dehui Huang4, Jinhao Lyu1, Mengjie Fang2, Jianxing Hu1, Yali Zang2, Dekang Zhang1, Hang Shao5, Lin Ma1, Jie Tian2, Di Dong2, Xin Lou1.   

Abstract

BACKGROUND: Precise diagnosis and early appropriate treatment are of importance to reduce neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) morbidity. Distinguishing NMOSD from MS based on clinical manifestations and neuroimaging remains challenging.
PURPOSE: To investigate radiomic signatures as potential imaging biomarkers for distinguishing NMOSD from MS, and to develop and validate a diagnostic radiomic-signature-based nomogram for individualized disease discrimination. STUDY TYPE: Retrospective, cross-sectional study.
SUBJECTS: Seventy-seven NMOSD patients and 73 MS patients. FIELD STRENGTH/SEQUENCE: 3T/T2 -weighted imaging. ASSESSMENT: Eighty-eight patients and 62 patients were respectively enrolled in the primary and validation cohorts. Quantitative radiomic features were automatically extracted from lesioned regions on T2 -weighted imaging. A least absolute shrinkage and selection operator analysis was used to reduce the dimensionality of features. Finally, we constructed a radiomic nomogram for disease discrimination. STATISTICAL TESTS: Features were compared using the Mann-Whitney U-test with a nonnormal distribution. We depicted the nomogram on the basis of the results of the logistic regression using the rms package in R. The Hmisc package was used to investigate the performance of the nomogram via Harrell's C-index.
RESULTS: A total of 273 quantitative radiomic features were extracted from lesions. A multivariable analysis selected 11 radiomic features and five clinical features to be included in the model. The radiomic signature (P < 0.001 for both the primary and validation cohorts) showed good potential for building a classification model for disease discrimination. The area under the receiver operating characteristic curve was 0.9880 for the training cohort and 0.9363 for the validation cohort. The nomogram exhibited good discrimination, a concordance index of 0.9363, and good calibration in the primary cohort. The nomogram showed similar discrimination, concordance (0.9940), and calibration in the validation cohort. DATA
CONCLUSION: The diagnostic radiomic-signature-based nomogram has potential utility for individualized disease discrimination of NMOSD from MS in clinical practice. LEVEL OF EVIDENCE: 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:1113-1121.
© 2018 International Society for Magnetic Resonance in Medicine.

Entities:  

Year:  2018        PMID: 30408268     DOI: 10.1002/jmri.26287

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

Review 1.  Emerging Applications of Radiomics in Neurological Disorders: A Review.

Authors:  Houman Sotoudeh; Amir Hossein Sarrami; Glenn H Roberson; Omid Shafaat; Zahra Sadaatpour; Ali Rezaei; Gagandeep Choudhary; Aparna Singhal; Ehsan Sotoudeh; Manoj Tanwar
Journal:  Cureus       Date:  2021-12-01

2.  Quantitative Susceptibility Mapping-Derived Radiomic Features in Discriminating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder.

Authors:  Zichun Yan; Huan Liu; Xiaoya Chen; Qiao Zheng; Chun Zeng; Yineng Zheng; Shuang Ding; Yuling Peng; Yongmei Li
Journal:  Front Neurosci       Date:  2021-12-03       Impact factor: 4.677

3.  Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Immunoautophagy-Related Genes and Tumor Microenvironment.

Authors:  Zhen Sun; Zhenhua Lu; Rui Li; Weiwei Shao; Yangyang Zheng; Xiaolei Shi; Yao Li; Jinghai Song
Journal:  Int J Gen Med       Date:  2021-09-08

4.  Constructing and validating a diagnostic nomogram for multiple sclerosis via bioinformatic analysis.

Authors:  Hao Li; Yong Sun; Rong Chen
Journal:  3 Biotech       Date:  2021-02-16       Impact factor: 2.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.